RTS,S/AS01, based on Plasmodium falciparum sporozoite circumsporozoite protein (CSP), was the first malaria vaccine (and the first anti-parasite vaccine) prequalified by the WHO for routine use, paving the way for GAVI and the Vaccine Alliance via UNICEF to secure a supply of 18 million doses for 2023–2025 to be used for children in regions with moderate to high malaria transmission [3,6,7,8]. This evidence concerns the gene DNAJC5 and malaria.